Pre-diagnostic beta-blocker use and head- and neck cancer risk: A nationwide population-based case-control study.

Abstract

β-blockers have been reported to exhibit potential anticancer effects in various cancer studies. However, few clinical studies concerning head and neck cancer have been conducted. We hypothesized that β-blockers could decrease the incidence of head and neck cancer. Therefore, we investigated the association between β-blocker treatment and head and neck cancer incidence.Between January 2006 and December 2015, we selected 12,127 patients with head and neck cancer for this nationwide study using data from the Korean Health Insurance Review and Assessment Service. The patients were matched 1:5 with 60,635 control participants according to age, sex, and, region. Logistic regression analysis was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) of cancer associated with β-blocker treatment. In the analysis, a crude (simple), adjusted model (adjusted model for age, sex, income, region of residence, hypertension, diabetes, and hyperlipidemia) was used.The OR for head and neck cancer incidence was not lower in the β-blocker cohort (OR: 1.18; 95% CI: 1.105–1.26), especially for the oral cavity (OR: 1.165; 95% CI: 1.013–1.340), hypopharynx (OR: 1.555; 95% CI: 1.232–1.963), nasopharynx (OR: 1.251; 95% CI: 1–1.564), and paranasal sinus (OR: 1.378; 95% CI: 1.027–1.849). The duration of β-blocker use was not related to head and neck cancer incidence.This study did not provide evidence that β-blockers can decrease the risk of head and neck cancer.